Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality.

Ørsted DD, Bojesen SE, Kamstrup PR, Nordestgaard BG.

Eur Urol. 2013 Sep;64(3):384-93. doi: 10.1016/j.eururo.2013.01.028.

PMID:
23398767
2.

Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.

Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE.

Eur Urol. 2012 May;61(5):865-74. doi: 10.1016/j.eururo.2011.11.007.

PMID:
22104593
3.

Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.

Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P.

Eur Urol. 2013 Jan;63(1):88-96. doi: 10.1016/j.eururo.2012.08.001.

PMID:
22902040
4.

A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.

Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M.

Eur Urol. 2015 Oct;68(4):591-7. doi: 10.1016/j.eururo.2014.04.005.

PMID:
24794075
5.

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; ERSPC Rotterdam Study Group..

Eur Urol. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030.

PMID:
23759326
6.
7.

Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.

Cancer. 2007 Apr 15;109(8):1689-95.

8.

Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.

Berger AP, Deibl M, Strasak A, Bektic J, Pelzer AE, Klocker H, Steiner H, Fritsche G, Bartsch G, Horninger W.

Urology. 2007 Jan;69(1):134-8.

PMID:
17270635
9.

Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer in Chinese men.

Zheng XY, Zhang P, Xie LP, You QH, Cai BS, Qin J.

Asian Pac J Cancer Prev. 2012;13(11):5529-33.

10.

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J.

Eur Urol. 2013 Jan;63(1):101-7. doi: 10.1016/j.eururo.2012.08.066.

PMID:
22980443
11.

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.

Fang J, Metter EJ, Landis P, Carter HB.

Urology. 2002 Jun;59(6):889-93; discussion 893-4.

PMID:
12031375
12.
13.

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.

Vickers AJ, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Pettersson K, Roobol MJ, Aus G, Scardino PT, Hugosson J, Schröder FH, Lilja H.

Eur Urol. 2009 Nov;56(5):753-60. doi: 10.1016/j.eururo.2009.07.047.

14.

The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.

Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, D'Amico AV.

Cancer. 2008 Aug 15;113(4):717-22. doi: 10.1002/cncr.23609.

15.

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.

O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, Scardino PT, Eastham JA, Vickers AJ, Lilja H.

J Clin Oncol. 2009 Aug 1;27(22):3591-7. doi: 10.1200/JCO.2008.19.9794.

16.

Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.

Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J.

Eur Urol. 2013 Nov;64(5):703-9. doi: 10.1016/j.eururo.2013.05.024. Erratum in: Eur Urol. 2015 Aug;68(2):e46.

PMID:
23721957
17.

Usefulness of prostate-specific antigen velocity in screening for prostate cancer.

Ito K, Yamamoto T, Ohi M, Kubota Y, Fukabori Y, Kurokawa K, Suzuki K, Yamanaka H.

Int J Urol. 2002 Jun;9(6):316-21.

18.

Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.

Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P.

Eur Urol. 2011 Sep;60(3):554-63. doi: 10.1016/j.eururo.2011.05.047.

PMID:
21664039
19.

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.

Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013.

PMID:
21601352
20.

Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.

Bul M, van den Bergh RC, Rannikko A, Valdagni R, Pickles T, Bangma CH, Roobol MJ.

Eur Urol. 2012 Feb;61(2):370-7. doi: 10.1016/j.eururo.2011.06.027.

PMID:
21704447
Items per page

Supplemental Content

Support Center